Compare Star Bulk Carriers Corp (SBLK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Star Bulk Carriers Corp vs TG Therapeutics Inc — how do they compare? Star Bulk Carriers Corp trades at $29.8 (market cap $3.54B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 2.3× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 6.17% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Star Bulk Carriers Corp for 24 Days and TG Therapeutics Inc for 16 Days on average.
| SBLK | TGTX | |
|---|---|---|
Market Cap | $3.54B | $8.16B |
Volume | 1,437,622 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $32.49 | $59.06 |
52-Week Low | $16.79 | $26.94 |
Typical Hold Time | 24 Days | 16 Days |
Enterprise Value | $4.22B | $8.37B |
Dividend Yield | 6.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Star Bulk Carriers (SBLK) trades at $29.75, up 0.2% today, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals, with Q2 2026 EPS of $1.21 beating estimates by 27% and a 45% year-over-year revenue surge. A $0.90 dividend for H2 2026 reflects robust free cash flow generation. Analyst consensus is strongly positive, with 14 buys out of 24 ratings, supported by recent insider buying activity.
The outlook for SBLK remains favorable due to consistent earnings beats, attractive valuation multiples, and management's commitment to returning capital. Key risks include shipping rate volatility and broader economic sensitivity. The stock presents a compelling opportunity for value and income investors, though exposure to cyclical industry trends warrants monitoring.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
